Cardiology overview congenital heart disease: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
* The benefit of PFO closure is not well established | * The benefit of PFO closure is not well established | ||
* The benefit of [[Coumadin]] in the patient with PFO is not well established, and this therapy should be reserved for those patients with [[atrial fibrillation]] or [[venous thromboembolism]]. | * The benefit of [[Coumadin]] in the patient with PFO is not well established, and this therapy should be reserved for those patients with [[atrial fibrillation]] or [[venous thromboembolism]]. | ||
==Ventricular Septal Defect== | |||
* Small in size defects do not require repair. | |||
==References== | ==References== | ||
Revision as of 20:53, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Atrial Septal Defect
Treatment
- An atrial septal occluder device can be used. There can be migration or erosion of the device so follow-up is warranted.
Coarctaion
- May be associated with bicuspid aortic stenosis
- Imaging follow-up is recommended to look for aneurysm formation.
Mitochondrial Cardiomyopathy
- Mitochondrial cardiomyopathy is associated with an increase in the pCO2 due to a reduction in ventilation.
Patent Foramen Ovale (PFO)
Treatment
- In the PFO patient who has had their first cryptogenic stroke, the treatment of choice as aspirin.
- The benefit of PFO closure is not well established
- The benefit of Coumadin in the patient with PFO is not well established, and this therapy should be reserved for those patients with atrial fibrillation or venous thromboembolism.
Ventricular Septal Defect
- Small in size defects do not require repair.